Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation

NCT03061006 | Completed Phase 4 Results FDA Drug

• 1 other identifier: 1050164
• Study Type: interventional
• Target: 101
• Locations: 1 country
• Sites: 1

Brief Summary

Patients will be screened at Intermountain Medical Center and at Intermountain-affiliated anticoagulation clinics in the Salt Lake City region. Patients with non-valvular atrial fibrillation will be considered for study. After written informed consent is obtained, subjects who meet eligibility criteria will be randomized 1:1 to 2 treatment arms: Group 1: Dabigatran etexilate (150 mg BID if CrCL \> 30 mL/min, or 75 mg BID if CrCL \> 15 to 30 mL/min or per USPI; and Group 2: Warfarin (Dose-adjusted (INR 2.0 - 3.0). Assessment of kidney function every 6 months will be done for Group 1. Standard warfarin follow-up and education, based upon system criteria, will be done for Group 2. All subjects will be followed for 24 months, and will be assessed at 1-week, then 3-, 6-, 12-, 18- and 24-months post-anticoagulation visits as well as other visits deem necessary for clinical care. All subjects will undergo protocol-specified laboratory tests and will complete 6 standard, validated questionnaires at each follow-up visit following the week 1 visit, except at the 3-month visit when only one questionnaire will be administered. To determine brain volume and characteristic changes representative of micro-bleeding, the first 10 subjects in each treatment group who are willing and able to undergo the procedure will participate in a MRI sub-study. The cranial MRI will be done at baseline and at 24-months post-anticoagulation on this sub-group.

Conditions

Dementia; Cognition Disorders; Cerebral Ischemic Events

Outcome Measures

Primary Outcomes (2)

• Number of Participants With Incident Dementia Determined by a Formal Diagnosis of Dementia by a Neurologist

  Incident dementia will be determined by a formal diagnosis of dementia by a neurologist

  24 months

• Number of Participants With Moderate Decline in Cognitive Function Based on Results of the Alzheimer's Disease Assessment Scale and the Disability Assessment for Dementia.

  Determined by measuring the change from baseline to study conclusion on the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog11, with scores ranging from 0 to 70, and higher scores indicating greater impairment) and the Disability Assessment for Dementia (DAD, with scores ranging from 0 to 100, and higher scores indicating less impairment). An increase in ADAS-cog11 of \>30% is considered significant for moderate cognitive decline. In subjects that score \<50% on the DAD, there is a direct correlation with global deterioration scales and scores. Subjects with a 30% decrease in DAD score or those with a score \<50% will be considered to have moderate cognitive decline. These scores will be aggregated and if a patient meets either one of the cognitive decline definitions they will be deemed positive for cognitive impairment.

  24 months

Secondary Outcomes (3)

• Number of Participants With Stroke or Transient Ischemic Attack (TIA) or Intracranial Bleed

  24 months

• Percent Change From Baseline in Mini-Mental State Examination Scores.

  24 months

• Changes From Baseline Scores on the Hachinski Ischemic Scale

  24 months

Study Arms (2)

Dabigatran Etexilate

EXPERIMENTAL

150 mg BID (CrCL \> 30 mL/min) or 75 mg BID (CrCL 15-30 mL/min)

Drug: Dabigatran Etexilate

Warfarin

ACTIVE COMPARATOR

Dose-adjusted warfarin (INR: 2.0-3.0)

Drug: Warfarin

Interventions

Dabigatran Etexilate DRUG

150 mg BID (CrCL \> 30 mL/min) or 75 mg BID (CrCL \> 15 to 30 mL/min); Assessment of kidney function every 6 months.

Also known as: Pradaxa

Dabigatran Etexilate

Warfarin DRUG

Dose-adjusted (INR 2.0 - 3.0); Standard warfarin follow-up and education based upon system criteria.

Also known as: Coumadin

Warfarin

Eligibility Criteria

• Age: 65 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)

You may qualify if:

• Male or female \>65 years of age.
• Non-valvular atrial fibrillation documented by electrocardiogram, ambulatory event monitor, or telemetry within 12 months of enrollment.
• Moderate risk of thromboembolism based upon a CHADS score or CHADS2 Vasc score of ≥2.
• Ability to complete a mini-mental status evaluation.
• Ability to independently comprehend and complete a quality of life and dementia questionnaires.
• Ability to provide informed consent for study participation.
• Willing and able to comply with the prescribed follow-up tests and schedule of evaluations.

You may not qualify if:

• Inability to take an anticoagulant due to known or perceived bleeding risk.
• Known coagulopathy that may impact the choice, duration, efficacy and safety of anticoagulation therapy.
• Atrial Fibrillation in the setting of valvular heart disease. Valvular heart disease defined as any surgical valve, mitral stenosis, or moderate-severe valvular heart disease.
• Severe renal dysfunction, defined as a creatinine clearance rate \<15 mL/min (documented within the last 3 months).
• History of any form of dementia.
• A life expectancy less than 24 months.
• Inability to comply with the follow-up schedule.
• Current participation in a clinical investigation that includes an active pharmacologic treatment arm.
• Participation in any other clinical trials involving investigational or marketed products within 30 days prior to entry in the study.
• Other conditions that in the opinion of the Principal Investigator(s) may increase risk to the subject and/or compromise the quality of the clinical trial.
• Concurrent pharmacologic treatment that is required to treat a condition long-term in which concurrent use of dabigatran etexilate is contraindicated.
• Treatment with any anticoagulant drug for stroke prevention for more than 30 days.
• Aspirin and P2Y12 inhibitors (e.g. clopidogrel (Plavix), or prasugrel (Effient)) are not considered anticoagulant drugs.
• If the subject has received any anticoagulant drug for stroke prevention for less than 30 days, the Principal Investigator(s) or a Co-Investigator will decide whether or not the subject is eligible for this study
• The Principal Investigator(s) determine(s) that the subject is not eligible for participation in this research study.

Sponsors & Collaborators

• Intermountain Health Care, Inc.: lead
• Boehringer Ingelheim: collaborator

Study Sites (1)

Intermountain Heart Institute

Murray, Utah, 84143, United States

Location

Related Publications (1)

• Kwan J, Hafdi M, Chiang LLW, Myint PK, Wong LS, Quinn TJ. Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia. Cochrane Database Syst Rev. 2022 Jul 14;7(7):CD012269. doi: 10.1002/14651858.CD012269.pub2.

  PMID: 35833913 DERIVED

MeSH Terms

Conditions

Dementia; Cognition Disorders

Interventions

Dabigatran; Warfarin

Condition Hierarchy (Ancestors)

Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurocognitive Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Pyridines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Benzimidazoles; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; 4-Hydroxycoumarins; Coumarins; Benzopyrans; Pyrans

Limitations and Caveats

1. This was a vanguard analysis, so underpowered to detect differences in endpoints. 2. Long-term adherence was suboptimal. 3. Selection bias: patients were enrolled that were willing and able to complete the battery of cognitive tests, which may have selected a patient population that would perform better on these tests.

Results Point of Contact

• Title: Heidi May, PhD, MSPH, Cardiovascular Epidemiologist
• Organization: Intermountain Medical Center Heart Institute

heidi.may@imail.org

801-507-4701

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 9, 2017
• First Posted: February 23, 2017
• Study Start: March 30, 2017
• Primary Completion: March 15, 2021
• Study Completion: March 15, 2021
• Last Updated: May 12, 2026
• Results First Posted: May 12, 2026

Record last verified: 2022-11

Locations

US (1)